Industry Research Reports and Market Analysis at MindBranch.com
  

Evaluating Business Intelligence Opportunities in the Pharmaceutical Industry (Strategy Focus)

Product Type: Market Research Report
Published by: Datamonitor
Published: June 2007
Product Code: R313-23949
Description
Introduction

As market pressures demand increased innovation and shorter time-to-market product lifecycles, pharmaceutical companies are evaluating alternative business models, focusing on technologies such as business intelligence (BI) tools -for translational medicine.

Scope

  • Examines essential ingredients of sales strategies for BI vendors serving the pharmaceutical industry
  • Identifies strategies vendors should use to develop more effective relationships and drive solution sales
  • Offers profiles of leading vendors selling BI tools to the Big Pharma and Biotech market


  • Highlights

    Market factors are driving adoption of translational research and specifically BI solutions

    BI opportunities exist at several levels within the pharmaceutical market

    BI vendors with high market readiness will realize the most success in the pharmaceutical industry

    Reasons to Purchase

  • Understand how to evaluate market opportunities for BI solutions in the pharmaceutical market
  • Discover new ways to leverage relationships as a tool to drive market penetration
  • Gain insight into Datamonitor's perspective on what makes a vendor successful
  • Table of Contents
    DATAMONITOR VIEW
    CATALYST
    SUMMARY
    METHODOLOGY
    ANALYSIS
    Market factors are driving adoption of translational medicine and specifically BI solutions
    External pressures are driving pharmaceutical companies to embrace translational research
    Both cultural and technology barriers slow the progress of translational medicine
    BI opportunities exist at several levels within the pharmaceutical market
    Enterprise-class BI solutions have the power to evolve with an organization's changing business needs
    BI spending by end-user group in Big Pharma and Biotech differs significantly
    The industry requires vendors with high market readiness in translational medicine
    Market sizing information is necessary but insufficient for identifying which sector to target
    Vendors should consider four criteria when evaluating market opportunities
    Market presence influences client perception about a BI solution and its vendor
    Industry-specific solutions reflect domain expertise
    A sales force with industry experience will resonate with pharmaceutical clients
    Partnerships with niche vendors or academic medical centers (AMCs) build credibility
    BI vendors with high market readiness will realize the most success in the pharmaceutical industry
    A number of vendors have implemented successful strategies for BI in pharmaceuticals
    Genstruct
    GenoLogics Life Sciences Software Inc. (GenoLogics)
    Oracle
    SAS
    ACTIONS
    BI solutions for Biotech and Big Pharma are not one size fits...both
    Approach an attaractive opportunity through the market-readiness lens
    Partner with innovators
    APPENDIX
    Definitions
    Abbreviations
    Further reading
    Datamonitor Technology Consultancy
    Ask the analyst
    List of Figures
    Figure 1: The Big Pharma sector is the largest market opportunity in BI solutions ($ spent)
    Figure 2: BI spending by technology (services vs. software) 2006-2012
    Figure 3: Big Pharma will spend more on BI tools for clinical and sales & marketing application than Biotech
    Figure 4: A framework for evaluating BI market opportunities in the pharmaceutical industry
    Figure 5: Both horizontal and niche vendors offer valuable BI solutions for translational medicine
    Ordering and More Information
    Price and Delivery Options



    MindBranch has been the leading provider of industry and investment research from more than 550 independent research firms since 1992. With over 90,000 market research reports, MindBranch is your trusted source of competitive business intelligence.